Tag: Oncolytic virotherapy
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab
Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More